Model-informed Drug Development (MiDD) at nova

Nova’s modeling and simulation approach combines mathematical models of diseases and treatments with virtual patients into an integrated clinical trial simulation platform called jinkō. Nova builds disease and treatment computational models based on knowledge extracted from literature and data. To simulate a trial, we run those models on virtual patients with appropriate simulated scenarios (in silico experimental protocols) to predict the clinical efficacy of new drugs at the population level before in-human trials take place

Are you planning for your upcoming MiDD (Model-informed Drug Development) programs? Do you want to learn more about the methodology behind in silico clinical trials? Download our white paper.